cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?

Abstract P2-16-01: A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC)

(2014) V Dieras et al.   CANCER RESEARCH

C-Met in invasive breast cancer

(2013) Colan M. Ho-Yen et al.   CANCER

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

(2013) R. Katayama et al.   CANCER RESEARCH

Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer

(2013) M. J. Duffy et al.   CLINICAL CHEMISTRY

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

(2013) Lainie P. Martin et al.   GYNECOLOGIC ONCOLOGY

MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer

(2013) Yu Jin Kim et al.   INTERNATIONAL JOURNAL OF CANCER

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Developing biomarkers to predict benefit from HGF/MET pathway inhibitors

(2013) Hartmut Koeppen et al.   JOURNAL OF PATHOLOGY

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

(2013) M. Merchant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer

(2013) J. F. Knight et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MET: A Critical Player in Tumorigenesis and Therapeutic Target

(2013) C. R. Graveel et al.   Cold Spring Harbor Perspectives in Biology

Abstract 1738: Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitors

(2012) S Betty Yan et al.   CANCER RESEARCH

cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

(2012) K. P. Raghav et al.   CLINICAL CANCER RESEARCH

Targeted therapy for triple-negative breast cancer: Where are we?

(2012) Michael J. Duffy et al.   INTERNATIONAL JOURNAL OF CANCER

Parallel Lives Diverge

(2012) Daniel Rayson   JOURNAL OF CLINICAL ONCOLOGY

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

(2012) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

HGF-Induced PKCζ Activation Increases Functional CXCR4 Expression in Human Breast Cancer Cells

(2012) Songyin Huang et al.   PLoS One

c-MET Protects Breast Cancer Cells from Apoptosis Induced by Sodium Butyrate

(2012) Bo Sun et al.   PLoS One

EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

(2011) Jean-Charles Soria et al.   CANCER TREATMENT REVIEWS

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer

(2011) Francesca De Bacco et al.   JNCI-Journal of the National Cancer Institute

Gene expression profiling in breast cancer: classification, prognostication, and prediction

(2011) Jorge S Reis-Filho et al.   LANCET

Breast Cancer-Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown

(2011) S. Previdi et al.   MOLECULAR CANCER THERAPEUTICS

Directed Therapy of Subtypes of Triple-Negative Breast Cancer

(2011) L. A. Carey   ONCOLOGIST

Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells

(2010) F. Hochgrafe et al.   CANCER RESEARCH

Targeting the HGF/Met signalling pathway in cancer

(2010) Fabiola Cecchi et al.   EUROPEAN JOURNAL OF CANCER

Clinical implications ofMETgene copy number in lung cancer

(2010) Luca Toschi et al.   Future Oncology

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural basis for agonism and antagonism of hepatocyte growth factor

(2010) W. D. Tolbert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells

(2009) M R Finkbeiner et al.   ONCOGENE

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer

(2009) C. R. Graveel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

(2009) M. G. Ponzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells

(2008) K. L. Mueller et al.   CANCER RESEARCH

Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes

(2008) Anthony Gonçalves et al.   MOLECULAR & CELLULAR PROTEOMICS